Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
ADMS

Adamas Pharmaceuticals

$10.11

-0.94 (-8.51%)

04:55
12/05/18
12/05
04:55
12/05/18
04:55
Conference/Events
Adamas Pharmaceuticals management to meet with Piper Jaffray »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

ADMS

Adamas Pharmaceuticals

$11.05

0.82 (8.02%)

06:53
12/04/18
12/04
06:53
12/04/18
06:53
Conference/Events
Adamas Pharmaceuticals management to meet with Piper Jaffray »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

ITGR

Integer

$82.98

-0.38 (-0.46%)

, SNSS

Sunesis

$0.88

-0.14 (-13.73%)

08:08
11/28/18
11/28
08:08
11/28/18
08:08
Conference/Events
Piper Jaffray to hold a conference »

30th Annual Healthcare…

ITGR

Integer

$82.98

-0.38 (-0.46%)

SNSS

Sunesis

$0.88

-0.14 (-13.73%)

HOLX

Hologic

$43.66

0.72 (1.68%)

CUTR

Cutera

$20.80

0.03 (0.14%)

ALGN

Align Technology

$220.61

-2.62 (-1.17%)

HAIR

Restoration Robotics

$1.59

-0.1 (-5.92%)

ABMD

Abiomed

$313.66

2.74 (0.88%)

NEO

NeoGenomics

$16.27

-0.2 (-1.21%)

DXCM

DexCom

$123.93

-1.9 (-1.51%)

PODD

Insulet

$80.96

0.01 (0.01%)

SAGE

Sage Therapeutics

$103.60

-8.98 (-7.98%)

GKOS

Glaukos

$58.93

0.12 (0.20%)

CFRX

ContraFect

$2.08

-0.03 (-1.42%)

TNDM

TNDM

ADMS

Adamas Pharmaceuticals

$10.14

-0.86 (-7.82%)

ATRC

AtriCure

$32.10

-0.205 (-0.63%)

LOXO

Loxo Oncology

$139.11

-13.63 (-8.92%)

OMCL

Omnicell

$72.97

0.19 (0.26%)

CRSP

Crispr Therapeutics

$36.36

-0.09 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 29

    Nov

  • 30

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 04

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 19

    Dec

  • 19

    Mar

Over a month ago
ADMS

Adamas Pharmaceuticals

$11.45

-0.455 (-3.82%)

07:25
11/13/18
11/13
07:25
11/13/18
07:25
Initiation
Adamas Pharmaceuticals initiated at Leerink »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 27

    Nov

  • 27

    Nov

ADMS

Adamas Pharmaceuticals

$11.45

-0.455 (-3.82%)

16:45
11/12/18
11/12
16:45
11/12/18
16:45
Initiation
Adamas Pharmaceuticals initiated at Leerink »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 27

    Nov

  • 27

    Nov

ADMS

Adamas Pharmaceuticals

$12.24

-4.71 (-27.79%)

07:18
11/05/18
11/05
07:18
11/05/18
07:18
Recommendations
Adamas Pharmaceuticals analyst commentary at H.C. Wainwright »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ADMS

Adamas Pharmaceuticals

$12.24

-4.71 (-27.79%)

05:52
11/05/18
11/05
05:52
11/05/18
05:52
Downgrade
Adamas Pharmaceuticals rating change at Mizuho »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

ADMS

Adamas Pharmaceuticals

$16.81

0.29 (1.76%)

16:10
11/01/18
11/01
16:10
11/01/18
16:10
Earnings
Adamas Pharmaceuticals reports Q3 EPS ($1.22), consensus ($1.34) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 12

    Nov

ADMS

Adamas Pharmaceuticals

$18.20

0.85 (4.90%)

, AGIO

Agios Pharmaceuticals

$65.89

2.51 (3.96%)

05:18
10/15/18
10/15
05:18
10/15/18
05:18
Recommendations
Adamas Pharmaceuticals, Agios Pharmaceuticals, Alnylam, Alexion, Bluebird Bio, BioMarin, CymaBay, Crispr Therapeutics, Global Blood Therapeutics, Horizon Pharma, Jazz Pharmaceuticals, Ocular Therapeutix, Rigel Pharmaceuticals, Xencor analyst commentary at Piper Jaffray »

Piper lists names to own…

ADMS

Adamas Pharmaceuticals

$18.20

0.85 (4.90%)

AGIO

Agios Pharmaceuticals

$65.89

2.51 (3.96%)

ALNY

Alnylam

$82.00

2.51 (3.16%)

ALXN

Alexion

$121.91

2.62 (2.20%)

BLUE

Bluebird Bio

$125.92

-0.81 (-0.64%)

BMRN

BioMarin

$99.60

2.28 (2.34%)

CBAY

CymaBay

$10.19

0.19 (1.90%)

CRSP

Crispr Therapeutics

$37.74

0.85 (2.30%)

GBT

Global Blood Therapeutics

$33.01

1.46 (4.63%)

HZNP

Horizon Pharma

$18.27

0.23 (1.27%)

JAZZ

Jazz Pharmaceuticals

$158.82

3.42 (2.20%)

OCUL

Ocular Therapeutix

$6.09

-0.02 (-0.33%)

RIGL

Rigel Pharmaceuticals

$3.10

0.005 (0.16%)

XNCR

Xencor

$35.08

1.04 (3.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

  • 19

    Oct

  • 19

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 07

    Nov

  • 27

    Nov

  • 01

    Dec

  • 20

    Dec

  • 28

    Dec

  • 18

    Feb

ADMS

Adamas Pharmaceuticals

$17.79

-1.55 (-8.01%)

08:42
10/08/18
10/08
08:42
10/08/18
08:42
Hot Stocks
Adamas Pharmaceuticals presents final results from EASE LID 2 study of Gocovri »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.